Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb:31 Suppl 24:34-36.
doi: 10.1111/pai.13152.

Antihistamines: ABC for the pediatricians

Giuseppe Fabio Parisi  1 , Amelia Licari  2 , Maria Papale  1 , Sara Manti  1   3 , Carmelo Salpietro  3 , Gian Luigi Marseglia  2 , Salvatore Leonardi  1
Affiliations

Antihistamines: ABC for the pediatricians

Giuseppe Fabio Parisi et al. Pediatr Allergy Immunol. 2020 Feb.

Abstract

Antihistamines are currently one of the most commonly administered drugs in children. They are used to treat symptoms that depend on histamine release, namely allergic diseases, such as rhinitis, asthma, urticaria, and anaphylaxis. It is possible to distinguish first- and second-generation antihistamines. Pharmacological effects and therapeutic indications are similar, but second-generation antihistamines have fewer adverse effects because they are more selective for peripheral H1 receptors. Although they have been on the market for several years, there are still many adverse effects linked to the antihistamine safety profile, especially in the first years of life. Thus, many antihistamines are prescribed off-label, especially in children younger than 2 years of age, which is the age-group where most of the data on drug safety are lacking and many antihistamines are not recommended. This article aims to provide a practical update on the use of antihistamines in children.

Keywords: H1 receptors; antihistamines; children; histamine; pediatrician.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

REFERENCES

    1. Tatarkiewicz J, Rzodkiewicz P, Żochowska M, Staniszewska A, Bujalska-Zadrożny M. New antihistamines - perspectives in the treatment of some allergic and inflammatory disorders. Arch Med Sci. 2019;15(2):537-553.
    1. Ritchie AI, Farne HA, Singanayagam A, et al. Pathogenesis of viral infection in exacerbations of airway disease. Ann Am Thorac Soc. 2015;12(Suppl. 2):S115-S132.
    1. Motola D, Donati M, Biagi C, et al. Safety profile of H1-antihistamines in pediatrics: an analysis based on data from VigiBase. Pharmacoepidemiol Drug Saf. 2017;26(10):1164-1171.
    1. Fitzsimons R, van der Poel LA, Thornhill W, du Toit G, Shah N, Brough HA. Antihistamine use in children. Arch Dis Child Educ Pract Ed. 2015;100(3):122-131.
    1. Church MK, Maurer M, Simons FE, et al. Risk of first-generation H(1)-antihistamines: a GA(2)LEN position paper. Allergy. 2010;65:459-466.

MeSH terms

LinkOut - more resources